Using a Systematic Approach to Select Critical Process Parameters - Harmonized regulations call for a risk-based and systematic approach to evaluating and selecting CPPs. - BioPharm International

ADVERTISEMENT

Using a Systematic Approach to Select Critical Process Parameters
Harmonized regulations call for a risk-based and systematic approach to evaluating and selecting CPPs.


BioPharm International
Volume 25, Issue 7, pp. 52-54

SELECTING CPPS

The key steps to selecting CPPs and their application to process control are as follows:

  • Identify critical quality attributes (CQAs) for drug-product and substance
  • Select API, excipients, materials and container closure
  • Define all unit operations and process flow
  • Define all product and process specification limits
  • Achieve acceptable results for method validation of all analytical methods
  • Complete quality risk management for factor/response selection for all critical unit operations and materials
  • Explore the design space for all key factors identified during the risk assessment using design of experiments (DOE) or other multivariate methods
  • Determine the factor effect size and select all CPPs
  • Evaluate CPPs for ease of control and practical application to process control.

These steps are considered in detail below.

CQA identification. CQAs are those attributes that are important to the quality of the drug product and that remain consistent with those used in clinical studies. The industry generally associates them with ICH parameters, such as identity, purity, potency, stability, and safety. CQAs provide the justification and rationale of what is critical to function and what ultimately needs to be controlled to assure compliance and fit for use. CQAs are the foundation upon which the CPPs must be associated. Line-of-site between CPPs and CQAs is considered a major component of the drug-development strategy.

Ingredient, materials, and container closure. Key parameters and analytical methods that measure the attributes of the API, excipients, key materials, and packaging/container closure must be examined using a quality risk- management (QRM) approach. This approach focuses on finding those attributes that will be crucial to maintaining the quality and stability of the drug substance and drug product. Key findings of this review will be added to the list of candidate process parameters that need to be controlled. Output of a QRM material assessment can help to generate candidate CPPs.

Unit operation process definition. Identification of all unit operations and their associated equipment sets and equipment capabilities in upstream and downstream processes are crucial when selecting those parameters that need to be controlled to assure potency and drug lot consistency. Small changes in time, temperature, pH, and other variables may result in changes to API characteristic, yield and impurity profiles. Output of a QRM unit operation assessment will generate some candidate CPPs. Because biologics are extremely sensitive to processing, it is important that each unit operation is carefully evaluated for possible impacts to the large molecule and impurities.


blog comments powered by Disqus

ADVERTISEMENT

Moscow Hosts IFPMA Biosimilars Conference
May 17, 2013
AbbVie and Alvine Will Collaborate on Celiac Disease Therapy
May 15, 2013
FDA Issues Pharmacoepidemiologic Safety Study Guidance
May 14, 2013
USP Launches Initiative to Fight Counterfeit Drugs in Sub-Saharan Africa
May 13, 2013
Amgen Forms New Joint Venture to Commercialize Vectibix in China
May 13, 2013
Upcoming Conferences
UPCOMING CONFERENCES

Access Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA | July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA | August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA | August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA | August 20-21, 2013
Request Brochure

See All Conferences >>

ADVERTISEMENT

Author Guidelines
FindPharma
Source: BioPharm International,
Click here